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Abstract 
The progressive degenerative disorders, Alzheimer’s disease (AD) and type II diabetes mellitus 
(T2DM), are characterized by the accumulation of misfolded peptides [i.e., amyloid-b (Ab) and 
human islet amyloid polypeptide (hIAPP), respectively]. In addition, multiple factors, such as metal 
ions and reactive oxygen species (ROS), are shown to be interconnected and involved in these 
peptides’ aggregation and toxicity. The inter-relationship between Ab or hIAPP, metals, ROS, and 
toxicity is not clear, however. In order to gain a better understanding of this interconnection, chemical 
tools capable of targeting metal-associated peptides and modulating their reactivities (i.e., peptide 
aggregation, metal-peptide-induced ROS formation) have been developed. In Chapters 2 and 3, the 
investigations, including cytotoxicity, regulatory activity toward Ab-/metal-Ab-induced toxicity, and 
antioxidant activity, of small molecules, designed to target metal-Ab and control their reactivities, are 
described. Moreover, the initial studies of metal influence on hIAPP’s toxicity in living cells are 
discussed in Chapter 4. Overall, the overall studies in this thesis have provided insight into designing 
new chemical tools used for investigating multiple facets in AD and T2DM. 
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Figure 1.1. A model of the nucleation-dependent polymerization. Two phases, lag phase and 
elongation phase, are involved in the fibril formation. The soluble monomers are self associated to 
produce the initial nucleus and protofibrils during the nucleation period called lag phase. Nucleus 
forms are rapidly aggregated to generate fibrils in elongation phase. 
 
Figure 1.2. Summary of the mutual contributions of Ab, metals, and oxidative stress to the 
pathogenesis of Alzheimer’s disease (AD). Amyloid precursor protein (APP) is cleavaged by a-
secretase, b-secretase, and g-secretase. The nonamyloidogenic pathway is associated with activity of 
a-secretase and g-secretase producing Ab17-40/Ab17-42 that do not aggregate. Ab40 and Ab42 generated 
through cleavage of APP by b-secretase and g-secretase tend to aggregate (amyloidogenic pathway). 
Ab40/Ab42 aggregate to form oligomers and fibrills. Transition metal ions [i.e. Fe(II/III) (red spheres), 
Cu(I/II) (blue spheres), and Zn(II) (green spheres)] have been found in Ab plaques. Redox active 
metal ions [i.e., Cu(I/II) and Fe(II/III)] with Ab could enhace oxidative stress via Fenton-like 
reactions forming reactive oxygen species (ROS). 
 
Figure 1.3. A scheme of ROS generation by copper-bound Ab via Fenton-like reaction.  
 
Figure 1.4. The amino acid sequences of human islet amyloid polypeptide (hIAPP) and rat IAPP 
(rIAPP). Only six out of 37 residues in rIAPP (red) are different from the counterparts in hIAPP and 
peptide aggregation to form toxic species occurs for hIAPP but not rIAPP. 
 
Figure 2.1. Chemical structures of L2-b, ML, and their deriatives. L2-b, 4-nitro-N-(pyridin-2-
ylmethyl)aniline; L2D1, N1,N1-diethyl-N4-(pyridin-2-ylmethyl)benzene-1,4-diamine; L2D3, N1,N1-
dimethyl-N4-(quinolin-2-ylmethyl)benzene-1,4-diamine; L2D4, 4-morpholino-N-(pyridin-2-ylmethyl) 
aniline; L2D6, 3,5-dimethoxy-N-(pyridin-2-ylmethyl)aniline; L2D7, N1,N1-dimethyl-N4-(1-(pyridin-
2-yl)ethyl)benzene-1,4-diamine; L2D8, N1-((1H-pyrrol-2-yl)methyl)-N4,N4-dimethylbenzene-1,4-di 
amine; L2D9, N1,N1-dimethyl-N4-((1-methyl-1H-imidazol-2-yl)methyl)benzene-1,4-diamine; L2D10, 
N1-(pyridin-2-ylmethyl)benzene-1,4-diamine; L3-b, (E)-N,N-dimethyl-4-((pyridin-2-yl methylene) 
amino)aniline; L2-nitro, 4-nitro-N-(pyridin-2-ylmethyl)aniline; H1, quinolin-8-amine; H2, 2-methyl 
quinolin-8-amine; H3, methyl-8-aminoquinoline-2-carboxylate; H4, (8-aminoquinolin-2-yl)methanol; 
HM1a, 2-((quinolin-8-ylamino)methyl)phenol; HM2a, 2-(((2-methylquinolin-8-yl)amino)methyl) 
phenol; HM3a, methyl-8-((2-hydroxybenzyl)amino)quinoline-2-carboxylate; HM4a, 2-(((2-(hydroxy 
methyl)quinolin-8-yl)amino)methyl)phenol; HM1, 4-(dimethylamino)-2-((quinolin-8-ylamino)methyl) 
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phenol; HM2, 4-(dimethylamino)-2-(((2-methylquinolin-8-yl)amino)methyl)phenol; HM3, methyl-8-
((5-(dimethylamino)-2-hydroxybenzyl)amino)quinoline-2-carboxylate; ML, 4-(dimethyl lamino)-2-
(((2-(hydroxymethyl)quinolin-8-yl)amino)methyl)phenol. 
 
Figure 2.2. Antioxidant activity of the (a) L2-b and (b) ML derivatives determined by the TEAC 
assay using cell lysates. The TEAC values are relative to that of a vitamin E analogue, Trolox (6-
hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). 
 
Figure 2.3. Cytotoxicity studies with the L2-b derivatives in murine Neuro-2a neuroblastoma (N2a) 
cells. Cell viability upon treatment with compounds under conditions (a) without and with metal ions 
[(b) Cu(II) or (c) Zn(II)]. Condition: [compound] = 5–50 mM; [CuCl2 or ZnCl2] = 5–50 mM; 24 h; 
37 °C. The values of cell viability (%), obtained by the MTT assay, were calculated compared to cells 
treated with DMSO only (0-1%, v/v). Error bars represent the standard error from three independent 
experiments. 
 
Figure 2.4. Cytotoxicity studies with the L2-b derivatives in human neuroblastoma SK-N-BE(2)-M17 
(M17) cells. (a) Cell viability upon incubation with compounds in the absence and presence of CuCl2 
or ZnCl2. Cells were treated with a compound (20 mM) and/or a metal chloride salt (CuCl2 or ZnCl2; 
20 mM) under Ab-free conditions followed for 24 h at 37 °C. The values of cell viability (%), 
measured by the MTT assay after 24 h incubation, were calculated compared to cells treated only with 
DMSO (0-1%, v/v). Error bars represent the standard error from three independent experiments. 
 
Figure 2.5. Cytotoxicity studies with the ML derivatives in murine Neuro-2a neuroblastoma (N2a) 
cells. Cell viability upon treatment with compounds under conditions (a) without and with (b) CuCl2 
or (c) ZnCl2. Condition: [compound] = 5–25 mM; [CuCl2 or ZnCl2] = 10–20 mM; 24 h; 37 °C. The 
values of cell viability (%), obtained by the MTT assay, were calculated compared to cells treated 
only with DMSO (0-1%, v/v). The dotted lines (b and C) indicate the viability of cells incubated with 
CuCl2 or ZnCl2 (10-20 mM). Error bars represent the standard error from three independent 
experiments. 
 
Figure 2.6. Cytotoxicity studies with the ML derivatives in human neuroblastoma SK-N-BE(2)-M17 
(M17) cells. Cell viability upon treatment with compounds under conditions (a) without and with (b) 
CuCl2 or (c) ZnCl2. Cells were treated with various concentrations of compounds (5 mM, 10 mM, and 
25 mM). Cells were added with compounds (10 mM) and metal ions [Cu(II) or Zn(II); 10 mM]. The 
values of cell viability (%), obtained by the MTT assay after 24 h incubation at 37 °C, were calculated 
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compared to cells treated only with DMSO (0-1%, v/v). The dotted lines (b and C) indicate the 
viability of cells incubated with CuCl2 or ZnCl2 (10 mM). Error bars represent the standard error from 
three independent experiments. 
 
Figure 2.7. Effect of compounds on survival of cells incubated with metal-free Ab and metal-Ab. 
Cells were treated with Ab40/Ab42 [(a) 10 mM or (b) 20 mM], with/without metal ions [CuCl2 or ZnCl2; 
(a) 10 mM or (b) 20 mM], and the L2-b derivatives [(a) 10 mM or (b) 20 mM] for 24 h at 37 °C. (c) 
Effect of the ML derivatives on survival of cells incubated with metal-free Ab and metal-Ab. Cells 
were treated with Ab40/Ab42 (10 mM), with/without metal ions [CuCl2 or ZnCl2; 10 mM], and 
compounds (10 mM) for 24 h at 37 °C.  
 
Figure 3.1. Chemical structures of glycosylated polyphenols and their derivatives. Phlorizin, 1-(2,4-
dihydroxy-6-(((2S,3R,4R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phe- 
nyl)-3-(4-hydroxyphenyl)propan-1-one; Verbascoside, (2R,3R,4R,5R,6R)-6-(3,4-dihydroxy pheneth-
oxy)-5-hydroxy-2-(hydroxymethyl)-4-(((2S,3R,4R,5R)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran 
-2-yl)oxy)tetrahydro-2H-pyran-3-yl(E)-3-(3,4-dihydroxyphenyl)-acrylate; Rutin, 2-(3,4-dihydroxy 
phenyl)-5,7-dihydroxy-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2S,3R,4R,5S)-3,4,5-trihydroxyl- 
tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; F2, 
(2S,3R,4R,6R)-2-(3,5-dihydroxy-2-(3-(4-hydroxyphenyl)pro-panoyl)phenoxy)-6-((propionyloxy) 
methyl)tetrahydro-2H-pyran-3,4,5-triyl tripropionate; VPP, (2S,3R,4R,5S)-2-(((2R,3R,4S,5R,6R)-2-
(3,4-dihydroxyphenethoxy)-5-(((E)-3-(3,4-dihydroxyphenyl)acryloyl)oxy)-3-(propionyloxy)-6-((pro 
pionyloxy)methyl)tetrahydro-2H-pyran-4-yl)oxy)-6-methyltetrahydro-2H-pyran-3,4,5-triyl tripropio 
nate; R2, (2R,3R,4R,5S,6S)-2-(((2R,3R,4S,5R,6S)-6-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo 
-4H-chromen-3-yl)oxy)-3,4,5-tris(propionyloxy)tetrahydro-2H-pyran-2-yl)methoxy)-6-methyltetra 
hydro-2H-pyran-3,4,5-triyl tripropionate.  
 
Figure 3.2. Cu(II) binding studies of Phlorizin, F2, Verbascoside, VPP, Rutin, and R2 observed by 
UV-vis. Samples were incubated for 2 h with and without Cu(II) (0.5-10 equiv) at pH 7.4 at room 
temperature.  
 
Figure 3.3. Zn(II) binding of Verbascoside and VPP observed by 1H NMR. Samples were incubated 
for 30 min with ZnCl2 (0 or 1 equiv) in DMSO-d6 at room temperature. 
 
Figure 3.4. Antioxidant activity of Phlorizin, F2, Verbascoside, VPP, Rutin, and R2 evaluated by 
the cell lysate-based TEAC assay. The TEAC values are relative to a vitamin E analogue, Trolox (6-
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hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). 
 
Figure 4.1. Cytotoxicity studies of the human islet amyloid polypeptide (IAPP) in the rat insulinoma-
1 (INS-1) pancreatic b cell. Cells were treated with hIAPP [10 mM (gray bars) or 20 mM (black bars)], 
with/without a metal chloride salt [CuCl2 or ZnCl2, 70 mM (gray bars) or 140 mM (black bars)] 
followed by 24 h incubation at 37 °C. The values of cell viability (%), measured by the MTT assay, 
were calculated compared to cells treated with H2O only. Error bars represent the standard error from 
three independent experiments. 
 
Figure 4.2. Cytotoxicity studies of the Cu(II)-hIAPP in the rat insulinoma-1 (INS-1) pancreatic b cell. 
Cells were treated with hIAPP (20 mM) without and with CuCl2 (20-100 mM) and incubated for 24 h 
at 37 °C. The values of cell viability (%), measured by the MTT assay, were calculated compared to 
cells treated with H2O only. Error bars represent the standard error from three independent 
experiments. 
 
Figure 4.3. Cytotoxicity studies with hIAPP in the rat insulinoma-1 (INS-1) pancreatic b cell. Cell 
viability upon incubation time [(a) 6 h or (b) 24 h] after treatment with hIAPP and metal-hIAPP 
preincubated for 1 h, 2 h, 3 h, and 9 h. Cells were treated with samples incubated hIAPP (10-20 mM) 
without and with CuCl2 or ZnCl2 (70-140 mM) followed by 6 h or 24 h incubation at 37 °C. The 
values of cell viability (%), measured by the MTT assay after 24 h incubation, were calculated 
compared to cells treated with HEPES only. Error bars represent the standard error from three 
independent experiments. 
 
Figure 4.4. Cytotoxicity studies with the hIAPP in the rat insulinoma-1 (INS-1) pancreatic b cell. Cell 
viability upon treatment with metal-free hIAPP and metal-hIAPP preincubated for 3 h at 37 °C. Cells 
were treated with preincubated hIAPP (20 mM) with/without metal ions [(a) CuCl2, 20-200 mM; (b) 
ZnCl2, 60-200 mM] for 24 h incubation at 37 °C. The values of cell viability (%), obtained by the 
MTT assay, were calculated compared to cells treated with HEPES only. Error bars represent the 
standard error from three independent experiments. 
 
Figure 4.5. Cytotoxicity studies with the apoptosis reagents in the rat insulinoma-1 (INS-1) pancreatic 
b cell. Cell viability of hIAPP treated cells upon treatment of the apoptosis inhibitors (calpeptin or 
trehalose) or enhancer (bafilomycin) with various concentration of a compound. Condition: [hIAPP] = 
20 mM; [calpeptin] = 1.25-10 mM, [trehalose] = 100-150 mM, [bafilomycin] = 0.01-0.2 mM; 24 h; 
37 °C. The values of cell viability (%), obtained by the MTT assay, were calculated compared to cells 
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treated with DMSO only (0-1%, v/v). Error bars represent the standard error from three independent 
experiments. 
 
Figure 4.6. Cytotoxicity studies with the apoptosis reagents in the rat insulinoma-1 (INS-1) pancreatic 
b cell. Cells were treated with hIAPP (20 mM), with CuCl2 (60 mM), and compounds (calpeptin, 2-7 
mM; trehalose, 100 mM; bafilomycin, 0.01-0.05 mM) for 24 h at 37 °C. The values of cell viability 
(%), obtained by the MTT assay, were calculated compared to cells treated with DMSO only (0-1%, 
v/v). Error bars represent the standard error from three independent experiments. 
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Chapter 1. Protein Misfolding Diseases: Alzheimer’s Disease and Type II Diabetes Mellitus 
  
1.1.  Introduction 
The accumulation of peptide or protein aggregates is a pathological characteristics of numerous 
degenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s 
disease (HD), as well as metabolic diseases, including type II diabetes mellitus (T2DM).1 These 
protein deposits include abnormally aggregated peptides or proteins (called amyloids) [e.g., amyloid-
b (Ab) peptides and human islet amyloid polypeptides (hIAPP) for AD and T2DM, respectively].2,3  
The aggregation of amyloidogenic peptides is depicted by the “nucleation-dependent 
polymerization” model which involves two kinetic phases: lag phase and elongation phase (Figure 
1.1). Self assembly of the peptides generates small oligomeric and prefibrillar aggregates during the 
lag time. Around the end of the lag phase, these resulting, thermodynamically unstable species serve a 
template or nucleus for the following fibrillar growth during the elongation phase (Figure 1.1). Rapid 
expansion of nucleus leads to the formation of mature fibrils which are a major constituent of the 
peptide deposits. The kinetics of the amyloid aggregation process is sigmoidal as shown in Figure 
1.1,2,3 which is shown to be affected by various factors, including pH, temperature, agitation, and 
other external components (e.g., metal ions, small molecules, other proteins).4 The structure of 
amyloids upon aggregation is the formation and lateral stacking of b sheets along the axis of fibril 
growth, which can be detected by amyloid-specific dyes.5  
Amyloid-related toxicity has been interested in studying protein misfolding diseases.6-8 In this 
context, research efforts have been toward characterizing structures of amyloids, from monomers to 
mature fibrils, and toxic conformations.6,8,9 Structures and kinetics of amyloids, however, depend on 
multiple factors, including solvents, temperature, metal ions, and small molecules, which has made 
amyloid-related studies challenging.6,8,9 Such limitation on investigating chemistry of amyloids has 
hindered gaining a clear understanding of amyloid-triggered pathogenesis of diseases. Thus, effective 
therapeutics and diagnostics for amyloid-related diseases have not been developed until now. Based 
on the previous reports,10 the interconnection between amyloids, metal ions, and reactive oxygen 
species (ROS) has been linked to toxicity. Herein, the relationship between multiple facets (e.g., 
amyloids, metals, oxidative stress) and disease development is described.  
 
1.2. Amyloid-b, Metals, and Oxidative Stress in Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most prevalent form of dementia and a progressive disease that 
is characterized by impairment of brain functions related to living and memory ability. More than 24 
million people worldwide are affected with AD.11 Over $220 billion and estimated 17.7 billion hours 
per a year were spent to care and support AD patients in America.11,12 The population of the patients is 
predicted to increase by 40 percent by 2025.11 Along with such serious impacts of AD on the  
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Figure 1.1. A model of the nucleation-dependent polymerization. Two phases, lag phase and 
elongation phase, are involved in the fibril formation. The soluble monomers are self associated to 
produce the initial nucleus and protofibrils during the nucleation period called lag phase. Nucleus 
forms are rapidly aggregated to generate fibrils in elongation phase. 
 
economic and health care aspects in our society, the biggest concern is the lack of the cure for this 
disease. The currently available medications are unfortunately able only to relieve the symptoms for 
six months or one year. The fundamental etiology involved in AD initiation and progression has not 
been fully understood; thus, effective therapeutics have not been developed until now. Deposition of 
misfolded senile plaques and neurofibrillary tangles has a hallmark in the brain of AD. Senile plaques 
and fibrillary tangles are composed of aggregates of amyloid-b (Ab) and hyperphosphorylated tau 
proteins, respectively.2,3,13,14 
 
1.2.1. Amyloid-b (Ab). Two major isoforms of Ab peptides are Ab40 and Ab42 in the length of 40 and 
42 amino acid residues, respectively. Ab peptides are produced by proteolytic cleavage of the 
transmembrane, amyloid precursor protein (APP) (Figure 1.2). 3,23 APP can be cleaved by a-secretase, 
b-secretase, and g-secretase affording to different fragmentations (Figure 1.2).3 In the 
nonamyloidogenic pathway, cleavage of APP by a- and g-secretases produces Ab17-40 or Ab17-42 
(Figure 1.2). In the amyloidogenic pathway, APP is cleaved by b- and g-secretases generating Ab1-40 
and Ab1-42 (equal to Ab40 and Ab42, respectively) (Figure 1.2).
23,24  
Both Ab40 and Ab42 possess a net charge of -3 through the combination of the six negatively 
charged residues (D1, E3, D7, E11, E22, and D23) and the three positively charged residues (R5, K16, 
and K28) (Figure 1.2).10,15 Ab42 has two additional hydrophobic C-terminal residues (I41 and A42) 
which direct the peptide more aggregation prone than Ab40; thus, Ab42 is believed more 
pathogenic.15,21  
In the healthy brain, the production and clearance of Ab is well balanced by the activity of 
secretases and proteases; however, this balance is not maintained in the AD-affected brain, thus 
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showing peptide aggregate accumulation. Currently, soluble Ab oligomers over Ab fibrils have been 
suggested to be more neurotoxic.16,25 It is, however, still unclear whether main neurotoxic substances 
are fibrils or soluble oligomers.26,27 
 
1.2.2. Metals. Senile plaques in the AD-affected brain are observed to contain the high level of 
transition metals, such as Cu, Zn, and Fe (Cu, ca. 0.4 mM; Zn, ca. 1 mM; Fe, ca. 0.9 mM), with 
comparison to that in the healthy brain tissue.21 In vitro studies have shown that the increased level of 
metal ions is able to facilitate Ab aggregation, suggesting that the interaction of Ab with metal ions is 
involved in the process of Ab aggregation and ROS formation leading to toxicity.3,10,13 
Numerous studies have suggested that metal binding sites are located within 1-16 residues of 
Ab.28 Binding of Cu(II) to Ab in vitro prefers a square planar geometry showing two proposed 
coordination modes (component I and II) that are dependent on pH.22 Component I (Ia and Ib) is 
dominant at physiological pH while component II is observed at higher pH.10 At physiological pH 
(component I), Cu(II) is ligated by two nitrogen (N) donor atoms from His6 and His13 or His14, a N 
donor atom from the N-terminal amine group, and one oxygen (O) donor atom from Ala2 (carbonyl) 
while the coordination of Cu(II) in component II is composed of three N donor atoms from His6, 
His13, and His14 and one O donor atom from Ala2 (carbonyl).22,28,29 Binding affinity (Kd) of Cu(II) to 
Ab is reported in a range of picomolar to nanomolar while Kd of Zn(II) to Ab is approximately 
 
 
Figure 1.2. Summary of the mutual contributions of Ab, metals, and oxidative stress to the 
pathogenesis of Alzheimer’s disease (AD). Amyloid precursor protein (APP) is cleavaged by a-
secretase, b-secretase, and g-secretase. The nonamyloidogenic pathway is associated with activity of 
a-secretase and g-secretase producing Ab17-40/Ab17-42 that do not aggregate. Ab40 and Ab42 generated 
through cleavage of APP by b-secretase and g-secretase tend to aggregate (amyloidogenic pathway). 
Ab40/Ab42 aggregate to form oligomers and fibrills. Transition metal ions [i.e. Fe(II/III) (red spheres), 
Cu(I/II) (blue spheres), and Zn(II) (green spheres)] have been found in Ab plaques. Redox active 
metal ions [i.e., Cu(I/II) and Fe(II/III)] with Ab could enhace oxidative stress via Fenton-like 
reactions forming reactive oxygen species (ROS).  
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micromolar.29,30 Zn(II) is expected to coordinate with four to six ligands involving three His residues, 
an addition O donor atoms (from Asp1, Arg5, Glu11 or Tyr10) and an exogenous water molecule.10,28 
 
1.2.3. Oxidative Stress Induced by Metal-Ab. Redox active metal ions [i.e., Cu(I/II), Fe(II/III)] are 
involved in Fenton-like reactions producing ROS, such as superoxide anion (O2
•-), hydrogen peroxide 
(H2O2), and hydroxyl radical (•OH) (Figure 1.3).
3 These generated ROS damage biological molecules, 
such as DNA, proteins, and lipids. These interactions between metals and Ab facilitate ROS 
generation enhancing oxidative stress, which is considered to be a contributor to AD development.3,10 
 
 
Figure 1.3. A scheme of ROS generation by copper-bound Ab via Fenton-like reaction.  
 
1.3.  Human Islet Amyloid Polypeptide and Metals in Type II Diabetes Mellitus 
Type II diabetes mellitus (T2DM) is a metabolic disorder that is characterized by the 
misregulated glucose level. Three hundred eighty two million people worldwide are estimated to 
suffer from this disorder by 2013.34 Diabetes mellitus is classified into two types: type I diabetes and 
type II diabetes.34 Type I diabetes mellitus (T1DM) is characterized by the disruption of pancreatic b 
cells caused by T-cell autoimmune attack, leading to deficiency of insulin.2,34 On the other hand, 
T2DM is mainly associated with decreased insulin secretion and action as a result of insulin resistance 
that leads progressive dysfunction of b cells.34,35 T2DM, formerly called noninsulin-dependent 
diabetes mellitus (NIDDM), is the most common form of diabetes and accounts for more than 90 % of 
diabetics.2  
 
1.3.1. Human Islet Amyloid Polypeptide. An important causative factor of T2DM is the misfolded 
human islet amyloid polypeptide (hIAPP) that is a 37-residue amyloidogenic peptide, and is co-
located and co-secreted with insulin in response to stimulation of pancreatic b cells.34,36 hIAPP differs 
from the rat islet amyloid polypeptide (rIAPP) in only six of 37 residues, which makes different 
propensity of aggregation between hIAPP and rIAPP (Figure 1.4). rIAPP is known as a 
nonamyloidogenic peptide37 while hIAPP has strong intrinsic propensity to aggregate to form 
oligomers and fibrils that are thought to be toxic to b cells despite the physiological role of hIAPP, 
such as glycemic regulation by reducing gastric emptying and the rate of glucose intake in blood.4,34,36  
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Several mechanisms of the fibril formation of hIAPP in T2DM have been suggested.38 Among 
those, the most widely accepted mechanism is that accumulation and aggregation of hIAPP may result 
from its increased production and secretion by enhanced demand for insulin as a result of insulin 
resistance.38 The role and mechanism of hIAPP, however, are still unclear in the pathogenesis of 
T2DM.34 
 
 
Figure 1.4. The amino acid sequences of human islet amyloid polypeptide (hIAPP) and rat IAPP 
(rIAPP). Only six out of 37 residues in rIAPP (red) are different from the counterparts in hIAPP and 
peptide aggregation to form toxic species occurs for hIAPP but not rIAPP. 
 
1.3.2. Metal Ions and hIAPP. hIAPP is observed to have a similar kinetic for its fibril formation, 
compared to Ab, the nucleated growth mechanism (Figure 1.1), as well as the propensity to interact 
with transition metal ions [e.g., Cu(I/II) and Zn(I/II)].2 The effect of metal ions, however, have been 
shown to be different in aggregation rates between hIAPP and Ab.38,39 Zn(II) is involved in insulin 
synthesis, secretion, and signaling; thus Zn(II) plays an important role in glucose homeostasis as a 
result of insulin actions.40,41 The role of Zn(II) on hIAPP aggregation is not fully uncovered; however, 
many studies have shown that Zn(II) overall has an inhibitory effect on hIAPP aggregation at 
physiological pH, although the effect of Zn(II) towards lag and elongation phases depends on 
concentration and pH.2,4,32,39 Different from metal-Ab interaction, Cu(II) has been shown to inhibit 
the formation of mature hIAPP fibrils. Similar to metal-Ab, Cu(II)-hIAPP-mediated cytotoxicity can 
occur through Cu(II)-induced ROS overproduction and mitochondrial dysfunction, which could lead 
to apoptosis of b cells.38  
 
1.4.  Conclusion  
AD and T2DM are two most significant forms of amyloid diseases (called amyloidosis or 
protein misfolding diseases). Amyloidosis, including AD and T2DM, is featured by intra- or extra-
cellular deposition of misfoled peptide aggregates (Ab and hIAPP for AD and T2DM, respectively).2 
The aggregates of these proteins share common structural traits, such as formation and lateral stacking 
of b sheets which are propagated along the axis of fibril growth.5 Although numerous efforts have 
been made toward understanding amyloid-related pathogenesis for AD and T2DM, the identification 
of etiologies for both diseases has not been successful; thus, therapeutic development is still limited. 
Current studies present that amyloidogenic peptides, Ab and hIAPP, can interact with metal ions 
showing facilitation or inhibition of their aggregation. In addition, their interactions can be linked to 
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production of ROS, leading to oxidative stress.12,18,20 Therefore, the investigations on the 
interconnection between Ab or hIAPP, metal ions and ROS are necessary in order to gain a better 
understanding of amyloid-related cytotoxicity, which will allow us to construct effective therapeutics 
and diagnostics for AD and T2DM. 
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Chapter 2. Biological Studies of Small Molecules Rationally Designed to Target and Modulate 
Multiple Facets of Alzheimer’s Disease 
 
2.1.  Introduction 
Alzheimer’s disease (AD) is the most common form of dementia and the progressive brain 
disorder that lead to a loss of memory, thinking, and the other brain functions. More than 24 million 
people worldwide suffer from this disorder.1,2 A treatment for AD, however, has not been developed 
yet because the etiology of the disease has been unclear. The hallmark of AD is the deposition of 
amyloid-b (Ab) plaques and neurofibrillary tangles.3-5 In the AD-affected brain, the production and 
clearance of Ab peptides are mismatched so that Ab peptides are accumulated and tend to aggregate. 
Among various conformations of Ab, oligomeric forms have been suggested to be mainly responsible 
for toxicity in AD.6,7 In addition, Ab plaques contain high concentration of transition metals (e.g., Cu, 
ca. 0.4 mM; Zn, ca. 1 mM; Fe, ca. 0.9 mM) in the comparison to those in healthy brain tissues (e.g., 
Cu, ca. 70 mM; Zn, ca. 300 mM; Fe, ca. 300 mM).8,9 These metal ions are observed to facilitate Ab 
aggregation. In the case of redox active metal ions [i.e., Cu(I/II)], metal-bound Ab species are shown 
to generate reactive oxygen species (ROS) via Fenton-like reactions leading to oxidative stress.10-12 
Metal-Ab species have been proposed as an interconnector of these multiple factors (e.g., Ab, metals, 
ROS). In that context, the design of the compounds that can target metal-Ab species and modulate 
their reactivities [i.e., Ab aggregation, ROS production] is valuable to elucidate the role of metal-Ab 
in AD pathogenesis. We have rationally developed compounds to target and regulate the multiple 
facets via the incorporation approach that a metal chelation moiety is integrated into an Ab interaction 
framework in a single entity. For this effort, two classes of small molecules (L2D and ML derivatives, 
Figure 2.1) have been newly prepared and characterized. Herein, our studies of understanding a 
relationship between chemical structures, antioxidant activity, and cytotoxicity are presented along 
with their influence on cytotoxicity induced by metal-free and metal-associated Ab. 
 
2.2.  Results and Discussion 
2.2.1. Design Principle of the L2-b and ML Derivatives. The structures of L2-b, ML, and their 
derivatives are depicted in Figure 2.1. All ligands have structural portions for both metal chelation and 
Ab interaction (Figure 2.1a, blue and green dotted line, respectively) in order to interact with metal-
free Ab and/or metal-Ab species. In the series of L2-b, three major modifications were made in the 
backbone of L2-b. L2D1, L2D4, L2D6, L2D10, and L2-nitro are first designed to have structural 
variation on the dimethyl amino group of L2-b. This functionality is known to be critical for Ab 
interaction.13,14 Secondly, L2D7 and L3-b are produced by introduction of a methyl or azo moiety on 
the central portion of L2-b. Lastly, L2D3, L2D8, and L2D9 were constructed through the 
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replacement of the pyridine ring on L2-b with an extended aromatic ring structure, pyrrole, and 
mono-N-methylated imidazole, respectively. As shown in Figure 2.1b, ML is a tetradentate ligand that 
has strong binding affinities for Cu(II) and Zn(II) (1015 M-1 and 1011 M-1, respectively),9 which could 
be too high to chelate out metal ions from metal-Ab species and/or metalloproteins. In order to tune 
metal binding, three chemical classes were prepared (Figure 2.1b): (i) 8-Aminoqiunoline derivatives 
(H1, H2, H3, and H4); (ii) 2-((quinolin-8-ylamino)methyl)phenol derivatives (HM1a, HM2a, HM3a, 
and HM4a); (iii) ML derivatives (HM1, HM2, HM3, and ML).  
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Figure 2.1. Chemical structures of L2-b, ML, and their deriatives. L2-b, 4-nitro-N-(pyridin-2-
ylmethyl)aniline; L2D1, N1,N1-diethyl-N4-(pyridin-2-ylmethyl)benzene-1,4-diamine; L2D3, N1,N1-
dimethyl-N4-(quinolin-2-ylmethyl)benzene-1,4-diamine; L2D4, 4-morpholino-N-(pyridin-2-ylmethyl) 
aniline; L2D6, 3,5-dimethoxy-N-(pyridin-2-ylmethyl)aniline; L2D7, N1,N1-dimethyl-N4-(1-(pyridin-
2-yl)ethyl)benzene-1,4-diamine; L2D8, N1-((1H-pyrrol-2-yl)methyl)-N4,N4-dimethylbenzene-1,4-di 
amine; L2D9, N1,N1-dimethyl-N4-((1-methyl-1H-imidazol-2-yl)methyl)benzene-1,4-diamine; L2D10, 
N1-(pyridin-2-ylmethyl)benzene-1,4-diamine; L3-b, (E)-N,N-dimethyl-4-((pyridin-2-yl methylene) 
amino)aniline; L2-nitro, 4-nitro-N-(pyridin-2-ylmethyl)aniline; H1, quinolin-8-amine; H2, 2-methyl 
quinolin-8-amine; H3, methyl-8-aminoquinoline-2-carboxylate; H4, (8-aminoquinolin-2-yl)methanol; 
HM1a, 2-((quinolin-8-ylamino)methyl)phenol; HM2a, 2-(((2-methylquinolin-8-yl)amino)methyl) 
phenol; HM3a, methyl-8-((2-hydroxybenzyl)amino)quinoline-2-carboxylate; HM4a, 2-(((2-(hydroxy 
methyl)quinolin-8-yl)amino)methyl)phenol; HM1, 4-(dimethylamino)-2-((quinolin-8-ylamino)methyl) 
phenol; HM2, 4-(dimethylamino)-2-(((2-methylquinolin-8-yl)amino)methyl)phenol; HM3, methyl-8-
((5-(dimethylamino)-2-hydroxybenzyl)amino)quinoline-2-carboxylate; ML, 4-(dimethyl lamino)-2-
(((2-(hydroxymethyl)quinolin-8-yl)amino)methyl)phenol. 
 
2.2.2. Antioxidant Capacity of the L2-b and ML Derivatives. In order to assess the ability of 
compounds to scavenge free radicals, the Trolox equivalent antioxidant capacity (TEAC) assay using 
cell lysates was conducted.15,16 This assay measures the amount of ABTS cation radicals [ABTS•+; 
ABTS = 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)] in the absence and presence of 
compounds. L2D1, L2D3, L2D4, L2D6, L2D7, L2D8, L2D9, L2D10, and L2-b were observed to 
have greater antioxidant activity than a vitamin E analogue, Trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid) (Figure 2.2a). The ability of L3-b and L2-nitro to scavenge 
free radicals was not indicated. The azo group of L3-b may affect the stability of its overall structure 
thus preventing it from donating hydrogen or electron to radicals.17 The nitro group of L2-nitro is an 
electron withdrawing group, which makes the overall structure difficult to quench free radicals.17 In 
the case of the ML derivatives, the TEAC values of HM4a, HM1, HM2, HM3, and ML were 
observed to be much higher than that of Trolox by ca. 2.5- to 4-fold (Figure 2.2b). H1, H2, H4, 
HM1a, and HM2a indicated an antioxidant activity better than Trolox by a factor of ca. 1.5~2.0. H3 
showed similar ability to scavenge free radicals that of Trolox. In contrary, the antioxidant property of 
HM3a was not presented; thus dimethylamino group of ML derivatives may play an important role to 
scavenge free radicals. Overall, our results suggest that the amino group or dimethylamino group 
could be necessary for achieving antioxidant activity of small molecules. 
 
2.2.3. Cytotoxicity of the L2-b and ML Derivatives. Murine Neuro-2a neuroblastoma (N2a) cells 
were treated with various concentrations of compounds (5-50 mM) and incubated for 24 h in a 
humidified atmosphere with 5% CO2 at 37 °C. Cell survival was measured by the MTT assay [MTT = 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. From the L2-b derivatives, among the 
ligands modified on the dimethylamino group of L2-b, L2D1 and L2D6 showed a similar trend in 
cytotoxicity to L2-b as a function of concentration while L2D4 and L2D10 were indicated to be less 
toxic at higher concentrations (i.e., 50 mM) than L2-b (Figure 2.3a). Note that optical interference 
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Figure 2.2. Antioxidant activity of the (a) L2-b and (b) ML derivatives determined by the TEAC 
assay using cell lysates. The TEAC values are relative to that of a vitamin E analogue, Trolox (6-
hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). 
 
with MTT at 600 nm may show increased absorbance values from the samples containing L2D4 or 
L2D10 at higher concentrations. Upon addition of cells with L2D7 and L3-b, lower cell survival was 
observed than L2-b (Fig 2.3a). In the case of L2D3 and L2D8, cell viability was decreased when their 
concentrations were increased; however, L2D9 was indicated to be less toxic than L2-b, L2D3, and 
L2D8 (Figure 2.3a). The replacement of pyridine in L2-b with mono-N-methylated imidazole is 
shown to influence on cell survival more than that with pyrrole (for L2D8) or an additional aromatic 
ring moiety (for L2D3). In the presence of metal ions, cytotoxicity of the compounds was also 
investigated (Figures 2.3b and 2.3c). N2a cells were treated with a metal chloride salt [CuCl2 or ZnCl2] 
and a compound in a ratio of 1:1 for 24 h. The overall cell viability with the compounds was 
decreased in the presence of Cu(II) (Figure 2.3b). On the other hand, incubation of cells with Zn(II) 
and compounds was not observed to be toxic depending on ligand concentration (Figure 2.3c). 
In order to further determine a structure-toxicity relationship, cytotoxicity studies were carried 
out in a different cell line, human neuroblastoma SK-N-BE(2)-M17 (M17) cell line. M17 cells were 
first treated with or without metal ions [Cu(II) or Zn(II), 20 mM] and compounds (20 mM). Overall, 
small molecules, except for L2D1, L2D3, L2D8, and L2-nitro, showed slightly increased or similar 
cell viability (Figure 2.4), compared to that observed in N2a cells (Figure 2.3a-c). L2D1 presented 
higher cell viability in the absence and presence of Zn(II) than that with Cu(II) (Figure 2.4). This 
tendency of cell viability is contrast to that shown in N2a cells (Figures 2.3b and 2.3c). Cells treated 
with L2D3 and L2D8 in the presence of Cu(II) showed lower cell survival unlike N2a cells at similar 
concentration conditions (e.g., compound 20 mM for M17 cells and 25 mM for N2a cells) (Figures 
2.3b and 2.4). Upon additioof L2-nitro to metal-free or metal-treated M17 cells, ca. 65-70% cell 
viability was observed (Figure 2.4), indicating the nitro group may cause more cytotoxicity than the 
dimethylamino functionality in L2-b. 
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Figure 2.3. Cytotoxicity studies with the L2-b derivatives in murine Neuro-2a neuroblastoma (N2a) 
cells. Cell viability upon treatment with compounds under conditions (a) without and with metal ions 
[(b) Cu(II) or (c) Zn(II)]. Condition: [compound] = 5–50 mM; [CuCl2 or ZnCl2] = 5–50 mM; 24 h; 
37 °C. The values of cell viability (%), obtained by the MTT assay, were calculated compared to cells 
treated with DMSO only (0-1%, v/v). Error bars represent the standard error from three independent 
experiments. 
 
 
Figure 2.4. Cytotoxicity studies with the L2-b derivatives in human neuroblastoma SK-N-BE(2)-M17 
(M17) cells. (a) Cell viability upon incubation with compounds in the absence and presence of CuCl2 
or ZnCl2. Cells were treated with a compound (20 mM) and/or a metal chloride salt (CuCl2 or ZnCl2; 
20 mM) under Ab-free conditions followed for 24 h at 37 °C. The values of cell viability (%), 
measured by the MTT assay after 24 h incubation, were calculated compared to cells treated only with 
DMSO (0-1%, v/v). Error bars represent the standard error from three independent experiments. 
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In the case of the ML derivatives, cell viability of ML and its derivatives was also determined. 
The toxicity of compounds was first investigated with their multiple concentrations (5 mM, 10 mM, 
and 25 mM) in both N2a and M17 cell lines. Upon addition of compounds, N2a cells indicated similar 
cell viability (close to ca. 100%) (Figure 2.5a). On the contrary, the ML derivatives exhibited 
approximately 20 % decreased cell viability (Figure 2.6a). Especially, HM2a, HM3a, HM1, HM2, 
and HM3 showed noticeably reduced cell survival at 25 mM (Figure 2.6a). Furthermore, upon 
addition of compounds, Cu(II)-treated cells were shown to be less survived with comparison to cells 
incubated only with compounds without metal ions (Figures 2.5b and 2.6b). Different from Cu(II), ca. 
90-100% cell viability was observed from cells treated with Zn(II) and most of compounds (except 
for HM3a in M17 cells) (Figures 2.5c and 2.6c). Taken together, in both N2a and M17 cell lines, 
similar cell viability with compounds was indicated despite structural variation. In addition, 
compounds were shown to be relatively toxic in M17 cells in the absence and presence of metal ions 
(Figures 2.6b and 2.6c) 
 
 
Figure 2.5. Cytotoxicity studies with the ML derivatives in murine Neuro-2a neuroblastoma (N2a) 
cells. Cell viability upon treatment with compounds under conditions (a) without and with (b) CuCl2 
or (c) ZnCl2. Condition: [compound] = 5–25 mM; [CuCl2 or ZnCl2] = 10–20 mM; 24 h; 37 °C. The 
values of cell viability (%), obtained by the MTT assay, were calculated compared to cells treated 
only with DMSO (0-1%, v/v). The dotted lines (b and C) indicate the viability of cells incubated with 
CuCl2 or ZnCl2 (10-20 mM). Error bars represent the standard error from three independent 
experiments 
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2.2.4. Influence of the L2-b and ML Derivatives on Cytotoxicity Induced by Metal-free Ab and 
Metal-Ab.  
The ability of compounds to regulate cytotoxicity induced by metal-free Ab and metal-Ab was 
determined in N2a cells. Note that L3-b was not included for this study due to its own 
toxicity with or without Cu(II) (Figure 2.3). From Ab-treated N2a cells, ca. 90-95% cell viability 
with and without metal ions was observed (Figure 2.7a). Upon addition of compounds, cytotoxicity 
induced by Ab40/Ab42 and metal-Ab40/Ab42 was regulated by L2D1, L2D3, L2D4, L2D7, L2D8, 
L2D9, L2D10, and L2-b to different extents. Under metal-free conditions, most of the ligands (except 
for L2D3 and L2D8) mitigated cytotoxicity of Ab (Ab40 or Ab42) by 5-15% while cell viability was 
not recovered by L2D3 and L2D8 with Ab40 and Ab42 treated living cells after treatment of ligands 
(Figure 2.7a). The noticeable effect on attenuation in cytotoxicity was not observed by compounds for 
Cu(II)-Ab (particularly, Ab42), although several ligands (L2D4, L2D6, L2D7, L2D10, and L2-b) 
triggered an increase in the viability of Cu(II)-Ab40-treated cells. In contrary, all ligands showed the 
ability to suppress Zn(II)-Ab-induced cytotoxicity (Figure 2.7a). Using M17 cells, modulation of Ab-
/metal-Ab-induced toxicity by the L2-b derivatives was also confirmed (Figure 2.7b).  
 
 
 
Figure 2.6. Cytotoxicity studies with the ML derivatives in human neuroblastoma SK-N-BE(2)-M17 
(M17) cells. Cell viability upon treatment with compounds under conditions (a) without and with (b) 
CuCl2 or (c) ZnCl2. Cells were treated with various concentrations of compounds (5 mM, 10 mM, and 
25 mM). Cells were added with compounds (10 mM) and metal ions [Cu(II) or Zn(II); 10 mM]. The 
values of cell viability (%), obtained by the MTT assay after 24 h incubation at 37 °C, were calculated 
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compared to cells treated only with DMSO (0-1%, v/v). The dotted lines (b and C) indicate the 
viability of cells incubated with CuCl2 or ZnCl2 (10 mM). Error bars represent the standard error from 
three independent experiments. 
 
In the case of the ML derivatives, the effect of small molecules to regulate toxicity induced by 
metal-free Ab/metal-Ab was investigated in N2a cells. Cells were treated with Ab (10 mM) and 
compounds [HM3a, HM4a, HM1, HM2, HM3, and ML (10 mM)] in the absence and presence of 
metal ions [Cu(II) or Zn(II), 10 mM]. All compounds, except for HM3a, were shown to mitigate 
cytotoxicity upon introduction of Ab/metal-Ab (Figure 2.7c). Overall, Ab-/metal-Ab-induced 
cytotoxicity was attenuated by L2-b, ML and their derivatives to different extents, which might be 
affected by structural variables of ligands. 
 
 
 
Figure 2.7. Effect of compounds on survival of cells incubated with metal-free Ab and metal-Ab. 
Cells were treated with Ab40/Ab42 [(a) 10 mM or (b) 20 mM], with/without metal ions [CuCl2 or ZnCl2; 
(a) 10 mM or (b) 20 mM], and the L2-b derivatives [(a) 10 mM or (b) 20 mM] for 24 h at 37 °C. (c) 
Effect of the ML derivatives on survival of cells incubated with metal-free Ab and metal-Ab. Cells 
were treated with Ab40/Ab42 (10 mM), with/without metal ions [CuCl2 or ZnCl2; 10 mM], and 
compounds (10 mM) for 24 h at 37 °C.  
 
2.3.  Conclusions 
We have designed small molecules that can target and regulate multiple factors (e.g., 
Ab/metal-Ab, metal ions, free radicals) that are suggested to contribute to AD development. In 
particular, the development of small molecules showing minimal toxicity and beneficial antioxidant 
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activity is challenging but valuable to be potential candidates for future biological use. In this chapter, 
our studies of elucidating a relationship between chemical structures (the L2-b and ML derivatives), 
antioxidant activity, and cytotoxicity are described. The L2-b/ML derivatives were shown to exhibit 
antioxidant activity and cytotoxicity although the structural modifications from the parent molecules 
to different extents. Our results and observations regarding a structure-antioxidant activity-
cytotoxicity relationship could provide guidance in designing small molecules applicable for 
biological applications.  
 
2.4.  Experimental Sections 
2.4.1. Ab Preparation. Ab peptides were dissolved in ammonium hydroxide (NH4OH, 1% v/v, aq), 
aliquoted, lyophilized overnight, and stored at –80 °C. A stock solution of Ab was prepared by 
dissolving the lyophilized peptide in 1% NH4OH (10 mL) followed by dilution with ddH2O. The 
concentration of Ab peptides in the solution was determined by measuring the absorbance of the 
solution at 280 nm (e = 1450 and 1490 M-1cm-1 for Ab40 and Ab42, respectively).  
 
2.4.2. Trolox Equivalent Antioxidant Capacity (TEAC) Assay. The antioxidant activity was 
determined by the TEAC assay employing cell lysates following the protocol of the antioxidant assay 
kit purchased from Cayman Chemical Company (Ann Arbor, MI, USA) with modifications.16,18 The 
N2a cells were used for this assay. This cell line purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA) was maintained in media containing 50% Dulbecco’s 
modified Eagle’s medium (DMEM) and 50% OPTI-MEM (GIBCO), supplemented with 10% fetal 
bovine serum (FBS, Sigma), 1% non-essential amino acids (NEAA, GIBCO), 2 mM glutamine, 100 
U/ml penicillin, and 100 mg/ml streptomycin (GIBCO). The cells were grown and maintained at 
37 °C in a humidified atmosphere with 5% CO2. For the antioxidant assay using cell lysates, cells 
were seeded in a 6 well plate and grown to approximately 80-90% confluence. Cell lysates were 
prepared following the previously reported method with modifications.19 N2a cells were washed once 
with cold PBS (pH 7.4, GIBCO) and harvested by gently pipetting off adherent cells with cold PBS. 
The cell pellet was generated by centrifugation (2,000 x g for 10 min at 4 °C). This cell pellet was 
sonicated on ice (5 sec pulses, 5 times with 20 sec intervals between each pulse) in 2 mL of cold 
Assay Buffer (5 mM potassium phosphate, pH 7.4, containing 0.9% n and 0.1% glucose). The cell 
lysates were centrifuged at 5,000 x g for 10 min at 4 °C. The supernatant was removed and stored on 
ice until use. To standard and sample 96 wells, 10 mL of the supernatant of cell lysates was delivered 
followed by addition of compound, metmyoglobin, ABTS, and hydrogen peroxide in order. After 5 
min incubation at room temperature on a shaker, absorbance values at 750 nm were recorded. The 
final concentrations (0.015, 0.030, 0.045, 0.060, 0.075, and 0.090 mM) of compounds and Trolox 
(Sigma-Aldrich; dissolved in DMSO) were used. The percent inhibition was calculated according to 
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the measured absorbance (% Inhibition = (A0-A)/A0, where A0 is absorbance of the supernatant of 
cell lysates) and was plotted as a function of compound concentration. The TEAC value of ligands 
was calculated as a ratio of the slope of the standard curve of the compound to that of Trolox. The 
measurements were conducted in triplicate. 
 
2.4.3. Cell Viability Studies. The N2a and M17 neuroblastoma cell lines were purchased from ATCC. 
For the M17 cell line, 50% minimum essential medium (MEM) and 50% F12 were added instead of 
50% DMEM, 50% OPTI-MEM, and 1% non-essential amino acids (NEAA, GIBCO). The cells were 
grown and maintained at 37 °C in a humidified atmosphere with 5% CO2. Cell viability upon 
treatment of compounds was determined using the MTT assay (Sigma). Cells were seeded in a 96 
well plate (15,000 cells in 100 mL per well). The N2a and M17 cells were treated with or without Ab 
and CuCl2 or ZnCl2, followed by the addition of compounds (1% v/v final DMSO concentration) and 
incubated for 24 h. After incubation, 25 mL MTT [5 mg/mL in phosphate buffered saline (PBS), pH 
7.4, GIBCO, Grand Island, NY, USA] was added to each well and the plate was incubated for 4 h at 
37 °C. Formazan produced by the cells was solubilized using an acidic solution of N,N-
dimethylformamide (50%, v/v aq) and sodium dodecyl sulfate (SDS, 20%, w/v) overnight at room 
temperature in the dark. The absorbance was measured at 600 nm using a microplate reader. Cell 
viability was calculated relative to cells containing an equivalent amount of DMSO. 
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Chapter 3. Investigations on Biochemical Activity of the Glycosylated Polyphenols and Their 
Esterified Derivatives toward Alzheimer’s Disease 
 
3.1.  Introduction 
Alzheimer’s disease (AD) is a growing concern for the global public health as the most 
desperate neurological disorder by the absence of fundamental treatments or cures for the disease.1 
While numerous potential therapeutics have been developed for AD, their clinical success and a 
rational discovery of the drugs are still limited due to unidentified causes and the lack of 
understanding of the disease progression.2,3,6 AD is a form of the protein misfolding diseases (called 
amyloidosis), characterized by the observation of the cellular deposits of the fibrillar peptide, senile 
plaques, and of the intraneuronal fibrillar tangles in the brain, composed primarily of amyloid-b (both 
the Ab40 and Ab42 isoforms) and hyperphosphorylated tau protein, respectively.
4-6 
The senile plaques found in the AD-affiliated brain have been shown to contain abnormally 
concentrated transition metals, Cu(I/II), Zn(II), and Fe(II/III). Especially, Zn(II) and Cu(II) have been 
proposed to accelerate the aggregation of Ab forming a variety of nonfibrillar aggregates along the 
aggregation pathway.7,8 Additionally, the interaction of Ab with redox active metals like Cu(I/II) and 
Fe(II/III) could facilitate the production of reactive oxygen species (ROS) via Fenton-like reactions, 
which promotes oxidative stress in the diseased brain.9,10,13 The potential interconnection of Ab, 
metals, and ROS on the AD pathogenesis makes it difficult to characterize causes and their influence 
on the disease onset and progression. Small molecules targeting a variety of metal-Ab that have been 
proposed as an interconnector of multiple factors (e.g., Ab, metals, metal-Ab, ROS) have been 
developed either through rational design or screening of natural products.11,12 Additionally, given the 
observations on the increase in oxidative stress found in the AD-affected brain, compounds with 
antioxidant capacity could also be beneficial.6,13 Herein, natural polyphenolic glycosides (Phlorizin, 
Verbascoside, and Rutin) and their esterifed derivatives (F2, VPP, and R2, respectively) were 
selected and investigated in terms of metal binding property, antioxidant capacity and inhibitory 
activity toward cytotoxicity induced by metal-Ab.  
 
3.2.  Results and Discussion 
3.2.1. Design Consideration of Glycosylated Polyphenols and Their Esterified Derivatives. In 
order to develop natural small molecules that could target metal-Ab species, polyphenolic 
compounds, Phlorizin, Verbascoside, and Rutin were selected based on the previous reports (Figure 
3.1).14-19 Polyphenolic compounds have been shown to have potential antiamyloidogenic activity.14,15 
Both Verbascoside and Rutin have previously demonstrated the potential to redirect Ab aggregation 
toward nontoxic species,16-19 and phloretin, the nonglycosidic version of Phlorizin, has demonstrated 
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an ability to prevent membrane-associated aggregation of Ab.29 These preliminary studies examined 
aggregation in the absence of metal ions; thus the presence of known metal interaction moieties, 
phenol in Phlorizin and catechol in Verbascoside and Rutin, suggests that these compounds may be 
capable of simultaneously interacting with both Ab and metals.30,31 Moerover, all three compounds are 
known as antioxidants. In addition to three natural products, their derivatives, F2, VPP, and R2 were 
designed via selective esterification (Figure 3.1, orange).20,21 Esterification could provide many 
structural and functional benefits in the quest for an effective chemical tool toward metal-Ab. Ester 
formation of the compounds is in part employed to protect their functionality and enhance targeted 
delivery and which is primarily programed to release the proto-compound via enzymatic cleavage of 
ester groups within the cell.22 In addition, the introduction of alkyl groups during the esterification 
may improve the ability of the compounds to passively diffuse across the blood brain barrier (BBB) 
due to improved lipophilicity.12,23 Finally, the concomitant increase in the hydrophobicity of the 
compounds might give them better chance to act with Ab/metal-Ab species via a nonpolar 
interaction.6,24  
 
 
Figure 3.1. Chemical structures of glycosylated polyphenols and their derivatives. Phlorizin, 1-(2,4-
21 
 
dihydroxy-6-(((2S,3R,4R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phe- 
nyl)-3-(4-hydroxyphenyl)propan-1-one; Verbascoside, (2R,3R,4R,5R,6R)-6-(3,4-dihydroxy pheneth-
oxy)-5-hydroxy-2-(hydroxymethyl)-4-(((2S,3R,4R,5R)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran 
-2-yl)oxy)tetrahydro-2H-pyran-3-yl(E)-3-(3,4-dihydroxyphenyl)-acrylate; Rutin, 2-(3,4-dihydroxy 
phenyl)-5,7-dihydroxy-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2S,3R,4R,5S)-3,4,5-trihydroxyl- 
tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; F2, 
(2S,3R,4R,6R)-2-(3,5-dihydroxy-2-(3-(4-hydroxyphenyl)pro-panoyl)phenoxy)-6-((propionyloxy) 
methyl)tetrahydro-2H-pyran-3,4,5-triyl tripropionate; VPP, (2S,3R,4R,5S)-2-(((2R,3R,4S,5R,6R)-2-
(3,4-dihydroxyphenethoxy)-5-(((E)-3-(3,4-dihydroxyphenyl)acryloyl)oxy)-3-(propionyloxy)-6-((pro 
pionyloxy)methyl)tetrahydro-2H-pyran-4-yl)oxy)-6-methyltetrahydro-2H-pyran-3,4,5-triyl tripropio 
nate; R2, (2R,3R,4R,5S,6S)-2-(((2R,3R,4S,5R,6S)-6-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo 
-4H-chromen-3-yl)oxy)-3,4,5-tris(propionyloxy)tetrahydro-2H-pyran-2-yl)methoxy)-6-methyltetra 
hydro-2H-pyran-3,4,5-triyl tripropionate.  
 
3.2.2. Metal Binding Properties of Polyphenols. In order to understand the interaction of the 
compounds with metal ions, particularly Cu(II) and Zn(II), their metal binding properties are 
investigated by visible spectroscopy (UV-vis) or 1D 1H NMR. Cu(II) binding of Phlorizin/F2, 
Verbascoside/VPP, or Rutin/R2 was investigated using UV-vis; Zn(II) binding of Verbascoside and 
VPP were studied by 1H NMR due to a lack of significant optical changes in the spectra upon 
addition of ZnCl2. In the buffered aqueous solution (20 mM HEPES, pH 7.4), it was observed that the 
absorption spectra of the six polyphenols changed to different extents upon the titration of CuCl2 
(Figure 3.2). Addition of CuCl2 to solutions of either Phlorizin or F2 produced no significant shift in 
spectral features, possibly due to the weak affinity of the phenol moiety in both compounds for Cu(II) 
in solution (Figure 3.2). F2 showed a decrease in the overall spectral intensity upon titration of CuCl2; 
this may be the result of breakdown or oxidation catalyzed by the presence of Cu(II) in solution.28 
This tendency of Phlorizin and F2 may be understood as recognition of the absence of the catechol 
functionality in their structure. In contrary, titration of CuCl2 to both Verbascoside and VPP in 
solution induced a slight variation on the absorption bands at ca. 330 nm and 405 nm, suggesting 
potential interaction between both ligands and Cu(II) under this condition (Figure 3.2). The spectral 
change is found more dramatic in VPP than in Verbascoside, which suggests that esterification 
contributes on the Cu(II) interaction property of the compounds even though this chemical 
modification is directed to the peripheral sites of the proposed metal binding portion. The presence of 
Cu(II) did induce modest spectral changes in the spectrum of Rutin (Figure 3.2) causing a decrease in 
the primary peak ca. 330 nm and an increase in a shoulder ca. 425 nm upon addition of CuCl2. This 
likely is the result of the interaction between the catechol moiety and Cu(II).15,27 Finally, R2 
demonstrated minimal spectral change over the course of the titration, suggesting it has minimal or no 
interaction with Cu(II) (Figure 3.2). This suggests that esterification of the Rutin framework could 
change the interaction between the ligand and Cu(II). Both VPP and R2 were esterified from their 
parent compounds but the extent of change in Cu-induced spectral variation was different, which may 
indicate importance of overall structure on the metal binding property of the compounds. 
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Figure 3.2. Cu(II) binding studies of Phlorizin, F2, Verbascoside, VPP, Rutin, and R2 observed by 
UV-vis. Samples were incubated for 2 h with and without Cu(II) (0.5-10 equiv) at pH 7.4 at room 
temperature.  
 
The interaction between Verbascoside and VPP with Zn(II) in DMSO-d6 was investigated by 
1H NMR. After the addition of 2 equiv ZnCl2 to the solution, significant sharpening of all protons of 
the catechol OH groups was observed (Figure 3.3): Note that the assignment of individual signals of 
these protons is difficult to predict from our 1D NMR data.32 Peak sharpening may be due to an 
increased tumbling of these protons because the catechol OH group could have better solvation upon 
interaction with Zn(II). Overall, the results suggest that Verbascoside, VPP, Rutin, and R2 could 
potentially interact to Cu(II) and/or Zn(II) while Phlorizin and F2 did not as evidenced by metal-
induced UV-vis spectral shift of the ligands, which indicates the necessity of catechol moiety to 
interact with metal ions. 
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Figure 3.3. Zn(II) binding of Verbascoside and VPP observed by 1H NMR. Samples were incubated 
for 30 min with ZnCl2 (0 or 2 equiv) in DMSO-d6 at room temperature. 
 
3.2.3. Antioxidant Properties. The ability of these six polyphenols to scavenge free radicals [the 
ABTS cation radical (ABTS•+); ABTS = 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)] was 
probed by the Trolox equivalence antioxidant capacity (TEAC) assay using cell lysates (Figure 
3.4).25,26 Both Verbascoside and Rutin, two known antioxidants,30,32 scavenged ABTS•+ marginally 
better than Trolox (by a factor of ca. 2.0 and 1.5, respectively). VPP and Phlorizin showed a slightly 
lower ability to scavenge ABTS•+ relative to Trolox. R2 and F2, meanwhile, indicated a lower TEAC 
value than Trolox, suggesting a limited function as an antioxidant relative to the other compounds 
investigated herein. This, again, indicates that esterification of the sugar moiety alters the function of 
the Verbascoside framework. In this case, the antioxidant capacity of the framework was reduced by 
ca. 40% following esterification. This reduction in antioxidant capacity is surprising given the 
conservation of the catechol structures between Verbascoside and VPP which is thought to be 
potentially responsible for ABTS•+ quenching through semi-quinone and quinone formation.26,27  
 
3.2.4. Regulating Toxicity Induced by Metal-Free and Metal-Associated Ab in Living Cells. In 
the previous studies, Verbascoside and Rutin have been suggested to alleviate the toxicity of metal-
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free Ab species.17,19 We have probed this relationship further to examine the effect of these two 
compounds and VPP on the toxicity triggered by both metal-free Ab and metal–Ab in murine Neuro-
2a (N2a) neuroblastoma cells. Upon addition of Verbascoside (5-25 mM), cell viability was increased 
in both metal-free and metal-treated cells (ca. 90-100% cell survival; Figure 3.5a). In the case of 
esterified VPP (5-10 mM), the treatment with this compound (5-10 mM) presented approximately 90% 
cell survival without and with metal ions and showed ca. 70% decreased viability at 25 mM in the 
presence of either Cu(II) or Zn(II) (Figure 3.5a). In addition, Rutin indicated no significant impact on 
cell viability under any conditions (Figure 3.5a). 
 
 
Figure 3.4. Antioxidant activity of Phlorizin, F2, Verbascoside, VPP, Rutin, and R2 evaluated by 
the cell lysate-based TEAC assay. The TEAC values are relative to a vitamin E analogue, Trolox (6-
hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). 
 
The ability of Verbascoside, VPP, and Rutin to mitigate cytotoxicity induced by metal-free 
and metal-Ab was also investigated. Cells incubated with Ab (20 mM) with or without metal ions 
[Cu(II) or Zn(II); 20 mM] showed ca. 70-80% viability under all conditions (Figure 3.5b). The 
addition of Verbascoside (20 mM) to the cells preincubated with Ab in both the absence and presence 
of metal ions significantly improved cell viability (ca. 90-100%). VPP (20 mM), however, was 
generally unable to regulate cytotoxicity of the various Ab species; in the absence and presence of 
Cu(II), VPP decreased cell viability to levels lower than Cu(II)-Ab. Finally, the treatment of cells 
with Rutin (20 mM) minimally improved cell viability under all conditions. Overall, only 
Verbascoside is capable of attenuating the broad toxicity of both Ab and metal-Ab. Furthermore, 
esterification of this framework limited this observed regulatory activity toward Ab and metal-Ab in 
living cells.  
 
25 
 
 
 
Figure 3.5. Influence of Verbascoside, VPP, and Rutin on toxicity induced by Ab or metal-Ab in 
murine Neuro-2a neuroblastoma (N2a) cells. (a) Cytotoxicity of compounds with or without metal 
ions. Cells treated with compounds [Verbascoside, VPP, and Rutin (5-25 mM)] with or without 
various concentrations of a metal chloride salt (CuCl2 or ZnCl2; 5-25 mM) were incubated for 24 h at 
37 °C. (b) Influence of Verbascoside, VPP, and Rutin on cytotoxicity induced by metal-free Ab and 
metal-Ab species in N2a cells. Cells treated with Ab40/Ab42 (20 mM), a metal chloride salt (CuCl2 or 
ZnCl2; 20 mM), and a compound (Verbascoside, VPP, or Rutin; 20 mM) were incubated for 24 h at 
37 °C. Cell viability was determined by the MTT assay. The values of viability (%) were calculated 
compared to cells treated with DMSO only (0-1%, v/v). Error bars represent the standard error from 
three independent experiments.  
 
3.3. Conclusion 
The natural glycosylated polyphenols, Phlorizin, Verbascoside, and Rutin, along with their 
esterified derivatives, F2, VPP, and R2, were investigated for their potential to target multiple factors 
(e.g., Ab, metals, metal-Ab, free radicals) and modulate their reactivities. UV-vis and NMR studies 
demonstrated that both Verbascoside and VPP having catechol moieties are able to interact with 
Cu(II) and Zn(II). In addition, Verbascoside is shown to have an antioxidant capacity and no toxicity 
up to the concentration tested. Overall, our studies suggest Verbascoside as a promising framework 
for a multifunctional chemical reagent to interrogate the etiology of AD. In addition, synthetic 
derivatization of parent scaffolds showing functionality should be carefully carried out in order to 
maintain or improve their functions.  
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3.4.  Experimental Sections 
3.4.1. Metal Binding Studies. The interactions of Phlorizin, F2, Verbascoside, VPP, Rutin, and R2 
with Cu(II) and Zn(II) were determined by UV-vis or 1H NMR. A solution of ligands (25 mM in 
HEPES, pH 7.4, 150 mM NaCl) was prepared, treated with 0.5 to 10 equiv of CuCl2, and incubated at 
room temperature for 2 h (for Phlorizin, F2, Verbascoside, VPP, Rutin, and R2). The optical spectra 
of the resulting solutions were measured by UV-vis. The interaction of Verbascoside or VPP with 
ZnCl2 was observed by 
1H NMR (400 MHz). One equiv of ZnCl2 was added to a solution of 
Verbascoside or VPP (2 mM) in DMSO-d6; the resulting spectral shifts were recorded. 
 
3.4.2. Trolox Equivalent Antioxidant Capacity (TEAC) Assay. The antioxidant activity of 
Phlorizin, F2, Verbascoside, VPP, Rutin, and R2 was determined by the TEAC assay employing 
cell lysates following the protocol of the antioxidant assay kit purchased from Cayman Chemical 
Company (Ann Arbor, MI, USA) with modifications.33,34 The murine Neuro-2a (N2a) cells were used 
for this assay. This cell line purchased from the American Type Culture Collection (ATCC, Manassas, 
VA, USA) was maintained in media containing 50% Dulbecco’s modified Eagle’s medium (DMEM) 
and 50% OPTI-MEM (GIBCO), supplemented with 10% fetal bovine serum (FBS, Sigma), 1% Non-
essential Amino Acids (NEAA, GIBCO), 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml 
streptomycin (GIBCO). The cells were grown and maintained at 37 °C in a humidified atmosphere 
with 5% CO2. For the antioxidant assay using cell lysates, cells were seeded in a 6 well plate and 
grown to approximately 80-90% confluence. Cell lysates were prepared following the previously 
reported method with modifications.35 N2a cells were washed once with cold PBS (pH 7.4, GIBCO) 
and harvested by gently pipetting off adherent cells with cold PBS. The cell pellet was generated by 
centrifugation (2,000 x g for 10 min at 4 °C). This cell pellet was sonicated on ice (5 sec pulses, 5 
times with 20 sec intervals between each pulse) in 2 mL of cold Assay Buffer (5 mM potassium 
phosphate, pH 7.4, containing 0.9% NaCl and 0.1% glucose). The cell lysates were centrifuged at 
5,000 x g for 10 min at 4 °C. The supernatant was removed and stored on ice until use. To standard 
and sample 96 wells, 10 mL of the supernatant of cell lysates was delivered followed by addition of 
compound, metmyoglobin, ABTS, and hydrogen peroxide in order. After 5 min incubation at room 
temperature on a shaker, absorbance values at 750 nm were recorded. The final concentrations (0.015, 
0.030, 0.045, 0.060, 0.075, and 0.090 mM) of Phlorizin, F2, Verbascoside, VPP, Rutin, R2 and 
Trolox (Sigma-Aldrich; Trolox = 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; dissolved 
in DMSO) were used. The percent inhibition was calculated according to the measured absorbance (% 
Inhibition = (A0-A)/A0, where A0 is absorbance of the supernatant of cell lysates) and was plotted as a 
function of compound concentration. The TEAC value of ligands was calculated as a ratio of the slope 
of the standard curve of the compound to that of Trolox. 
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3.4.3. Cell Viability Studies. The N2a cell line was purchased from ATCC. The cells were grown and 
maintained at 37 °C in a humidified atmosphere with 5% CO2. Cell viability upon treatment of 
compounds was determined using the MTT assay (Sigma). N2a cells were seeded in a 96 well plate 
(15,000 cells in 100 mL per well). The cells were treated with or without Ab and CuCl2 or ZnCl2, 
followed by the addition of compounds (1% v/v final DMSO concentration for Verbascoside, VPP, 
and Rutin) and incubated for 24 h in the cells. After incubation, 25 mL MTT [5 mg/mL in phosphate 
buffered saline (PBS), pH 7.4, GIBCO, Grand Island, NY, USA] was added to each well and the plate 
was incubated for 4 h at 37 °C. Formazan produced by the cells was solubilized using an acidic 
solution of N,N-dimethylformamide (DMF, 50%, v/v aq) and sodium dodecyl sulfate (SDS, 20%, w/v) 
overnight at room temperature in the dark. The absorbance was measured at 600 nm using a 
microplate reader. Cell viability was calculated relative to cells containing an equivalent amount of 
DMSO. 
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Chapter 4. Investigations of Cytotoxicity Induced by the Human Islet Amyloid Polypeptide in 
the Absence and Presence of Metal Ions 
 
4.1.  Introduction 
Type II diabetes mellitus (T2DM) is the most prevalent form of diabetes and characterized by a 
deficit pancreatic b cell induced by increased levels of circulating insulin to overcome insulin 
resistance.1,2 The hallmark of type II diabetes is amyloid plaques composed of the human islet 
amyloid polypeptide (hIAPP) in pancreatic islets.3,4 hIAPP is a 37 amino acid residue that is normally 
co-secreted with insulin by pancreatic b cells and involved in glucose metabolism.4,5 hIAPP has the 
intrinsic propensity to self-associate to generate multiple conformations, e.g., oligomers, protofibrils, 
and fibrils, and the previous in vitro studies report that these aggregated forms could cause toxicity to 
b cells and increase their apoptosis.3,12 Furthermore, transition metal ions, such as Cu(II) and Zn(II), 
are suggested to be associated with the aggregation pathways of hIAPP; redox active metals [i.e., 
Cu(I/II)]-hIAPP is proposed to produce reactive oxygen species (ROS) via Fenton-like reactions.6,7 
Although the interaction between metal ions and hIAPP has been observed, a relationship between 
this interaction and toxicity has not been fully revealed. In addition, which hIAPP species (i.e., 
oligomers, fibers) cause cytotoxicity is still unclear.8 Herein, to get a better understanding of toxicity 
induced by hIAPP, results from cytotoxicity studies are described: investigations of (i) metal influence 
on hIAPP’s toxicity; (ii) hIAPP intermediates’ toxicity; (iii) apoptosis induced by hIAPP in the 
absence and presence of metal ions. 
 
4.2.  Results and Discussion 
4.2.1. Cytotoxicity of hIAPP in the Absence and Presence of Metal Ions. To investigate the 
cytotoxicity of hIAPP, rat insulinoma-1 (INS-1) pancreatic b cells were treated with hIAPP (10 or 20 
mM) without and with metal ions (CuCl2 or ZnCl2, 70-140 mM) and the cell viability was measured 
by the MTT assay [MTT= 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] upon 24 h 
incubation. Cells treated with hIAPP in the absence of metal ions showed cell viability ca. 80% 
(Figure 4.1). The cells are treated with hIAPP (10 or 20 mM) and metal ions in a ratio of 1:7 peptide to 
metal. Upon addition of CuCl2 (70 or 140 mM) to hIAPP-treated cells, cell viability was decreased by 
approximately 15% compared to that only with hIAPP (Figure 4.1). On the other hand, ca. 20% 
increased cell viability was observed when the cells were treated with hIAPP (10 mM) and ZnCl2 (70 
mM) while ca. 10% decreased viability was indicated upon treatment of cells with hIAPP (20 mM) and 
ZnCl2 (140 mM), relative to that with hIAPP only (Figure 4.1). From the observation that 
Cu(II)-hIAPP-treated cells showed the lowest viability (ca. 60%) (Figure 4.1), further toxicity studies 
were carried out with variation of the ratio of hIAPP to Cu(II) (from 1:1 to 1:5) (Figure 4.2). ca. 75% 
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viability of cells treated with hIAPP only was observed; the cell survival was reduced down to ca. 55% 
as the ratio of hIAPP to Cu(II) was increased (Figure 4.2). Overall, hIAPP was indicated to have 
different toxicity in the absence and presence of metal ions, particularly showing altered toxicity of 
Cu(II)-hIAPP depending on peptide to metal ratios. 
 
 
Figure 4.1. Cytotoxicity studies of the human islet amyloid polypeptide (hIAPP) in the rat 
insulinoma-1 (INS-1) pancreatic b cell. Cells were treated with hIAPP [10 mM (gray bars) or 20 mM 
(black bars)], with/without a metal chloride salt [CuCl2 or ZnCl2, 70 mM (gray bars) or 140 mM (black 
bars)] followed by 24 h incubation at 37 °C. The values of cell viability (%), measured by the MTT 
assay, were calculated compared to cells treated with H2O only. Error bars represent the standard error 
from three independent experiments. 
  
 
Figure 4.2. Cytotoxicity studies of the Cu(II)-hIAPP in the rat insulinoma-1 (INS-1) pancreatic b cell. 
Cells were treated with hIAPP (20 mM) without and with CuCl2 (20-100 mM) and incubated for 24 h 
at 37 °C. The values of cell viability (%), measured by the MTT assay, were calculated compared to 
cells treated with H2O only. Error bars represent the standard error from three independent 
experiments. 
 
4.2.2. Peptide Conformation-Dependent Cytotoxicity. In order to investigate cytotoxicity of metal-
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associated hIAPP species depending on the degree of their aggregation, INS-1 pancreatic b cells were 
treated with hIAPP that were preincubated with CuCl2 or ZnCl2 for different time periods (hIAPP, 10 
or 20 mM; hIAPP:M(II) = 1:7; preincubation time: 1, 2, 3, or 9 h) followed by incubation for 6 h 
(Figure 4.3a) or 24 h (Figure 4.3b) at 37 °C. Viability of the cells added with preincubated 
hIAPP/metal-hIAPP was obtained by the MTT assay. Cells treated with preincubated samples for 6 h 
did not show noticeable variation to each other depending on the preincubation time points of hIAPP 
or metal-hIAPP (ca. 80-90% cell survival) (Figure 4.3a). On the other hand, cells with hIAPP 
preincubated with Cu(II) presented changes in their viability upon 24 h incubation depending on the 
preincubation time points (Figure 4.3b). The lowest cell viability was observed in the cells treated 
with hIAPP preincubated with Cu(II) for 3 h (ca. 60%) (Figure 4.3b). These overall results suggest 
that the aggregated hIAPP forms that were generated at 3 h incubation time point may be toxic living 
cells. 
 
 
 
 
Figure 4.3. Cytotoxicity studies with hIAPP in the rat insulinoma-1 (INS-1) pancreatic b cell. Cell 
viability upon incubation time [(a) 6 h or (b) 24 h] after treatment with hIAPP and metal-hIAPP 
preincubated for 1 h, 2 h, 3 h, and 9 h. Cells were treated with samples incubated hIAPP (10-20 mM) 
without and with CuCl2 or ZnCl2 (70-140 mM) followed by 6 h or 24 h incubation at 37 °C. The 
values of cell viability (%), measured by the MTT assay after 24 h incubation, were calculated 
compared to cells treated with HEPES only. Error bars represent the standard error from three 
independent experiments. 
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In order to further investigate toxicity induced by metal-hIAPP, cytotoxicity studies were 
carried out with metal-hIAPP aggregates prepared after 3 h incubation [which indicated the lowest 
cell viability (Figure 4.3b)], upon varying metal ion concentrations. The INS-1 cells were treated with 
prepared metal-hIAPP (preincubated for 3 h; hIAPP, 20 mM; CuCl2, 20-200 mM or ZnCl2, 60-200 
mM). In the case of Cu(II)-hIAPP, cell viability was proportionally reduced as a function of the 
concentration of CuCl2 (Figure 4.4a). Different from Cu(II)-hIAPP, Zn(II)-hIAPP-treated cells 
exhibited no noticeable change in cell survival despite increasing the concentrations of ZnCl2 (Figure 
4.4b). Taken together, our results suggest that Cu(II)-hIAPP intermediates are potentially more toxic 
than Zn(II)-affiliated counterparts. 
 
 
Figure 4.4. Cytotoxicity studies with the hIAPP in the rat insulinoma-1 (INS-1) pancreatic b cell. Cell 
viability upon treatment with metal-free hIAPP and metal-hIAPP preincubated for 3 h at 37 °C. Cells 
were treated with preincubated hIAPP (20 mM) with/without metal ions [(a) CuCl2, 20-200 mM; (b) 
ZnCl2, 60-200 mM] for 24 h incubation at 37 °C. The values of cell viability (%), obtained by the 
MTT assay, were calculated compared to cells treated with HEPES only. Error bars represent the 
standard error from three independent experiments. 
 
4.2.3. Investigation of Apoptosis Induced by Metal-Free hIAPP or Metal-hIAPP. Previous studies 
have suggested that locally unstable membrane induced by toxic hIAPP oligomers cause cytoplasmic 
Ca(II) overproduction leading to endoplasmic reticulum (ER) stress and overactivation of Ca(II)-
sensitive protease called calpain;11 the cellular miscompartmentalization of Ca(II) could induce the b 
cell dysfunction and apoptosis in T2DM.11,12 From these previous studies, it is reported that misfolded 
peptide species can be degraded by b cell autophagy;13,14 thus its impairment may enhance cell death 
potentially via acceleration of hIAPP-induced b cell apoptosis.13,14 To better understand a contribution 
of hIAPP-/Cu-hIAPP-induced apoptosis on the associated cellular failure, cytotoxicity studies were 
carried out against hIAPP-/metal-hIAPP-affiliated cells in the absence and presence of the known 
apoptosis inhibitor (calpain inhibitor, calpeptin,11 or autophagy enhancer, trehalose13,14) or enhancer 
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(autophagy inhibitor, bafilomycin13,14). 
Toxicity induced by hIAPP or Cu(II)-hIAPP was modulated upon addition of the compounds. 
Upon treatment with an inhibitor, calpeptin or trehalose, hIAPP-associated cells presented an increase 
in survival by approximately 10-20% in the absence and presence of Cu(II) in accordance with their 
inhibition property to different extents depending on their concentrations. These results indicate that 
mitigation of the toxicity may attribute to attenuation of hIAPP-/Cu(II)-hIAPP-associated apoptosis 
mediated by the inhibitors (Figures 4.5 and 4.6). Bafilomycin decreased cell viability with hIAPP and 
Cu(II)-hIAPP regardless of its concentrations (ca. 40-50%) (Figures 4.5 and 4.6). Thus, Calpeptin, 
trehalose, and bafilomycin displayed the ability to control b cell death induced by hIAPP with or 
without Cu(II); hIAPP-/Cu(II)-hIAPP-induced cytotoxicity was attenuated by calpeptin or trehalose 
and deteriorated by bafilomycin. 
 
 
Figure 4.5. Cytotoxicity studies with the apoptosis reagents in the rat insulinoma-1 (INS-1) pancreatic 
b cell. Cell viability of hIAPP treated cells upon treatment of the apoptosis inhibitors (calpeptin or 
trehalose) or enhancer (bafilomycin) with various concentration of a compound. Condition: [hIAPP] = 
20 mM; [calpeptin] = 1.25-10 mM, [trehalose] = 100-150 mM, [bafilomycin] = 0.01-0.2 mM; 24 h; 
37 °C. The values of cell viability (%), obtained by the MTT assay, were calculated compared to cells 
treated with DMSO only (0-1%, v/v). Error bars represent the standard error from three independent 
experiments. 
 
4.3. Conclusion 
hIAPP is suggested to be a potential causative factor for the development of T2DM. Toxic 
intermediates of hIAPP can be generated during the abnormal aggregation process; however, several 
questions remain unclear: (i) how fibrillogenesis of hIAPP affects this disorder; (ii) how other factors 
(i.e., metals) interact with hIAPP and influence its fibril formation and toxicity. To help these 
questions, the toxicity of hIAPP with and without metal ions under various conditions was  
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Figure 4.6. Cytotoxicity studies with the apoptosis reagents in the rat insulinoma-1 (INS-1) pancreatic 
b cell. Cells were treated with hIAPP (20 mM), with CuCl2 (60 mM), and compounds (calpeptin, 2-7 
mM; trehalose, 100 mM; bafilomycin, 0.01-0.05 mM) for 24 h at 37 °C. The values of cell viability 
(%), obtained by the MTT assay, were calculated compared to cells treated with DMSO only (0-1%, 
v/v). Error bars represent the standard error from three independent experiments. 
 
investigated. From our studies, Cu(II)-hIAPP particularly, triggered an increase in cytotoxicity 
depending on metal concentration and intermediate formation generated at different incubation time 
periods. In addition, cytotoxicity mediated by hIAPP/metal-hIAPP was affected in the presence of an 
apoptosis inhibition (calpeptin or trehalose) or enhancer (bafilomycin). 
 
4.4.  Experimental Sections 
4.4.1. Samples Preparation. hIAPP peptides were dissolved in 100% Hexafluoro-2-propanol (HFIP), 
aliquoted, lyophilized overnight, and stored at -80 °C. A stock solution of hIAPP was prepared by 
dissolving the lyophilized peptide in distilled water. The concentration of hIAPP peptides in the 
solution was determined by measuring the absorbance of the solution at 280 nm (e = 1740 M-1cm-1) 
and then diluted at desired concentration into 20 mM HEPES, pH 7.5.15,16 To prepare preincubated 
peptide samples, hIAPP (200 mM) was incubated in presence and absence of metal ions (CuCl2 and 
ZnCl2, 1.4 mM) at 37 °C with 300 rpm agitation. 1, 2, 3, and 9 h incubated samples were collected 
and stored at -80 oC.  
 
4.4.2. Cell Viability Measurements. The rat insulinoma-1 (INS-1) pancreatic b cells were purchased 
from Addexbio. INS-1 cell line was maintained in media containing RPMI 1640 (GIBCO), 10% (v/v) 
fetal bovine serum (FBS, Sigma), 10 mM HEPES((4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid), 1 mM sodium pyruvate(GIBCO), 50 mM b-metcaptoethanol (GIBCO), 100 U/mL penicillin and 
100 U/mL streptomycin (GIBCO), 2 mM glutamine. The cells were grown and maintained at 37 °C in 
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a humidified atmosphere with 5% CO2. Cell viability upon treatment of compounds was determined 
using the MTT assay (Sigma). Cells were seeded in a 96 well plate (30,000 cells in 100 mL per well). 
The cells were treated with or without hIAPP and CuCl2 or ZnCl2 in the absence and presence of 
compounds (calpeptin, trehalose, and bafilomycin; 1% v/v final DMSO concentration) and incubated 
for 24 h in the cells. After incubation, 25 mL MTT (5 mg/mL in phosphate buffered saline (PBS), pH 
7.4, GIBCO, Grand Island, NY, USA) was added to each well and the plate was incubated for 4 h at 
37 °C. Formazan produced by the cells was solubilized using an acidic solution of N,N-
dimethylformamide (50%, v/v aq) and sodium dodecyl sulfate (SDS, 20%, w/v) overnight at room 
temperature in the dark. The absorbance was measured at 600 nm using a microplate reader. Cell 
viability was calculated in comparison to that of the untreated cells in percentage value (%). 
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